Article ID Journal Published Year Pages File Type
11025439 International Journal of Infectious Diseases 2018 6 Pages PDF
Abstract
The generic piperacillin-tazobactam was equivalent to the innovator piperacillin-tazobactam with regards to all-cause mortality, mortality by infection, hospital stay, and safety, and at a lower cost, which may be useful for decision-makers in hospitals.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Applied Microbiology and Biotechnology
Preview
Results of the effectiveness of two piperacillin-tazobactam molecules in the real world
Authors
, , ,